Abstract. Thymus carcinoma is one of the thymic epithelial neoplasms with high metastasis, which does not have any good treatment at present. High mobility group A2 (HMGA2) is highly expressed in a variety of malignant tumors, such as lung cancer, colon cancer and ovarian cancer and is closely related to tumor invasion and metastasis. The present study aimed to investigate the effect and mechanism of HMGA2 on epithelial-mesenchymal transition (EMT) in thymic cancer cells. IU-TAB-1, A549, HCT-116 and 293T cells were screened by testing the protein expression level of HMGA2 though western blotting and subjected to HMGA2 interfer [small interfering (si)-HMGA2]. Cell proliferation was evaluated using the Cell Counting Kit-8 assay. Cell migration and invasion were detected using the Transwell assay. Cell apoptosis was examined using flow cytometry and β-catenin expression was observed by immunofluorescence. The levels of E-cadherin, vimentin, Wnt3a, Wnt5a and β-catenin proteins were determined by western blotting. Among the four cell lines tested, IU-TAB-1 cells demonstrated the highest expression of HMGA2 (P<0.05) and were hence selected for subsequent experiments. Compared with the control group (untransfected cells), si-HMGA2 resulted in significantly decreased proliferation, migration and invasion of IU-TAB-1 cells, whereas apoptosis was increased (P<0.05). The protein expression of vimentin, Wnt3a, Wnt5a and β-catenin was significantly decreased by si-HMGA2 compared with the control group (P<0.05), whereas E-cadherin expression was increased (P<0.05). After treatment with si-HMGA2 in combination with Wnt/β-catenin agonists (SKL2001) or inhibitors (XAV-939), EMT was respectively enhanced or inhibited in IU-TAB-1 cells. Overall, si-HMGA2 may attenuate EMT in thymic cancer cells and the mechanism may be related to the Wnt/β-catenin pathway.

Introduction

Thymic epithelial tumors are rare malignant tumors of thymic origin that are mainly classified as thymoma, thymic cancer and thymic neuroendocrine tumors(1). Thymic cancer accounts for 20% of thymic epithelial tumors and exhibits a strong metastatic behavior (1). The average age of onset of thymic cancer is ~50 years, with ~50–65% of patients displaying distant metastases on diagnosis in China from 1962-2003 (2). Late and poor prognosis, and intrathoracic and distant metastases are the main causes of death due to thymic cancer (3). Currently, there is no effective treatment for thymic carcinoma, and post-treatment recurrence and tumor metastasis are the most important factors affecting patient prognosis and quality of life (3,4). Hence, the discovery of biomarkers and understanding of the molecular mechanisms of tumor recurrence and metastasis are of great significance for the diagnosis and treatment of thymic cancer.

High mobility group (HMG) proteins are a series of chromatin-related proteins widely present in eukaryotes and consisting of 3 families: HMGA, HMGB and HMGN (5). HMGA2 belongs to the non-histone chromosome HMGA family that exerts its function as a transcription factor by altering the structure of chromatin and the interaction of DNA and target protein (6). HMGA2 is highly expressed in embryonic and immature tissues, but is almost absent in differentiated and mature tissues (7). Studies have found that HMGA2 is also highly expressed in a variety of malignant tumors, such as lung cancer, ovarian cancer and colorectal cancer (8-12), and its enhanced expression is closely related to increased tumor invasiveness and disease prognosis (8-12). Hence, HMGA2 is considered as a potential tumor marker for all types of cancer.

Epithelial-mesenchymal transition (EMT) refers to the loss of polarity, tight junctions and adhesion connections between cells, and it is an effective way for epithelial cells to acquire migration ability and is the phenomenon underlying epithelial cell carcinoma invasion and metastasis (13). EMT is
not only related to normal embryonic development, but is also closely related to tumorigenesis and tumor development (14). Studies have demonstrated that EMT serves a pivotal role in the primary invasion and secondary metastasis of numerous types of cancer, including breast, colon, lung, prostate and liver cancer (15-17). During the occurrence of EMT, epithelial cells lose their polarity and contact with surrounding stromal cells is reduced. Meanwhile, cell migration and motility are enhanced and cells take on a mesenchymal phenotype while losing their epithelial phenotype (13). EMT can be induced by a variety of signaling pathways, such as the transforming growth factor-β, Wnt and Notch pathways. Wnt signaling can induce EMT in tumor cells by inhibiting glycogen synthase kinase 3β-mediated phosphorylation and β-catenin degradation in the cytoplasm (18,19).

The Wnt/β-catenin signaling pathway participates in regulating embryonic development and plays an indispensable role in tumor generation and development (19). A study has demonstrated that the expression of factors associated with Wnt/β-catenin in ovarian epithelial carcinoma tissues is significantly higher compared with that in benign ovarian tumor tissues (20). Huang et al (21) observed that the expression of Wnt/β-catenin in nasopharyngeal tissues of patients with nasopharyngeal carcinoma was significantly higher compared with that in normal control tissues. The aforementioned finding suggests that the occurrence and development of nasopharyngeal carcinoma is highly associated with abnormal Wnt/β-catenin signaling. To the best of our knowledge, few studies have investigated the association between HMGA2, WNT signaling and EMT in thymic cancer. Studies have reported that HMGA2 can affect the EMT of gastric cancer, tongue cancer and retinoblastoma by regulating the Wnt/β-catenin signaling pathway (22-24). Our previous study found that with the increase in clinical staging of thymic cancer, the expression of β-catenin gradually increased, suggesting that Wnt/β-catenin is closely related to thymic cancer (25). Hence, it was speculated that the abnormal expression of HMGA2 may activate the Wnt/β-catenin pathway and promote tumorigenesis. The present study aimed to investigate the effect and mechanism of HMGA2 on EMT in thymic cancer cells. HMGA2 interference vectors [small interfering (si)-HMGA2] were constructed to study the effect of HMGA2 on EMT in thymic cancer cells. Further molecular experiments were performed to verify whether these effects were achieved via the Wnt/β-catenin signaling pathway. The findings of the present study will provide some insights for the treatment of thymic cancer.

Materials and methods

Cell culture and transfection. IU-TAB-1, a thymic cancer cell line (cat. no. T8001), was obtained from Applied Biological Materials Inc. Cell lines 293T, A549 and HCT-116 (normal control cell lines) were kindly provided by the Stem Cell Bank of the Chinese Academy of Medical Sciences. IU-TAB-1, 293T, A549 and HTC-116 cells were cultured in RPMI 1640 (cat. no. SH30022.01B; Hyclone; Cytiva), Prigrow II (cat. no. TM002; Applied Biological Materials Inc.), F-12K (cat. no. 21127-022; Gibco; Thermo Fisher Scientific, Inc.) or McCoy’s 5A (cat. no. 16600-082; Gibco; Thermo Fisher Scientific Inc.) medium, respectively, supplemented with 10% fetal bovine serum (FBS; cat. no. 10270-106; Gibco; Thermo Fisher Scientific Inc.) in an atmosphere containing 5% CO₂ and 95% air at 37°C. The medium was replaced every 24 h and the cells were subcultured or cryopreserved in liquid nitrogen at -196.56°C when the confluence reached 70-80%.

The full-length cDNA of HMGA2 (NM_001300918.1) was obtained from the National Center for Biotechnology Information database (https://www.ncbi.nlm.nih.gov/search/all/?term=NM_001300918.1). IU-TAB-1 cells were transfected with HMGA2 siRNA using Lipofectamine® 2000 reagent (cat. no. 13778030; Invitrogen; Thermo Fisher Scientific Inc.) according to the manufacturer’s instructions. Briefly, 100 pmol siRNA and 5 µl Lipofectamine® RNAiMAX were added to 250 µl Opti-MEM at 4°C for 20 min, respectively, and then the above mixture was incubated at 37°C in a 5% CO₂ incubator for 48 h. The cell experiments were divided into 5 groups: i) Control (untransfected cells); ii) HMGA2-siRNA1; iii) HMGA2-siRNA2; iv) HMGA2-siRNA3; and v) non-targeting negative control. The transfection efficiency was detected by reverse transcription-quantitative PCR (RT-qPCR). Wnt signaling antagonist (XAV-939; cat. no. HY-15147; 4 µM) and agonist (SKL2001; cat. no. HY-101085; 30 µM) were purchased from MCE. XAV-939 and SKL2001 were added after the cells were stably transfected for 48 h and cultured in a constant temperature incubator at 37°C for 48 h.

Cell Counting Kit-8 assay. IU-TAB-1 cells were seeded in a 96-well plate at a density of 5x10⁴ cells/ml in Prigrow II medium containing 10% FBS. Following 48 h of treatment, 10 µl Cell Counting Kit-8 (CCK-8) solution (cat. no. C1706; Bioswamp Wuhan Biotechnology Co. Ltd.) was added to each well and the cells were cultured at 37°C for 4 h. Cell proliferation was examined by measuring the optical density at 450 nm using a plate reader (Multiskan FC; Thermo Fisher Scientific Inc.).

Transwell migration and invasion assays. IU-TAB-1 cells were cultured in serum-free Prigrow II medium for 24 h and resuspended in Prigrow II medium containing 1% FBS. Subsequently, the cells were seeded into Transwell chambers at 1x10⁵ cells/ml, while 0.75 ml of Prigrow II medium containing 10% FBS was added into the lower chambers. The plate was incubated in 5% CO₂ at 37°C for 48 h. Subsequently, 1 ml of 4% formaldehyde solution was added to each well, and the plate was incubated at 4°C for 10 min for immobilization. Following 30 min of incubation at room temperature with 0.5% crystal violet solution (cat. no. C1701; Bioswamp Wuhan Biotechnology Co. Ltd.), the cells were observed under a fluorescent microscope (magnification, ×200).

For cell invasion assay, the upper chambers were pre-coated with 80 µl of Matrigel (cat. no. 356234; BD Biosciences). The chambers were incubated at 37°C for 30 min for gel formation and hydrated in 1% FBS for 4 h before use. In the lower chambers, 750 µl Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS was added. Subsequently, IU-TAB-1 cells were added to the upper chambers at a density of 1x10⁵ cells/well and incubated for 48 h at 4°C. Next, 1 ml of 4% paraformaldehyde (cat. no. 10010018; Sinopharm Scientific Inc.) was added into the lower chambers. After 20 min, respectively, and then the above mixture was added into the lower chambers. The chambers were incubated in 5% CO₂ containing 10% FBS was added into the lower chambers. The plate was incubated in 5% CO₂ at 37°C for 48 h. Subsequently, 1 ml of 4% formaldehyde solution was added to each well, and the plate was incubated at 4°C for 10 min for immobilization. Following 30 min of incubation at room temperature with 0.5% crystal violet solution (cat. no. C1701; Bioswamp Wuhan Biotechnology Co. Ltd.), the cells were observed under a fluorescent microscope (magnification, ×200).
Table I. Primer sequences used for reverse transcription-quantitative PCR.

| Primer | Sequence (5'-3')             |
|--------|------------------------------|
| HMGA2-F | TTCAGCCCAAGGGACAA           |
| HMGA2-R | CCAGGCAAGGCAACAT           |
| GAPDH-F | CCACGCTCCACCTTTG          |
| GAPDH-R | CACCCACCTGTTGCTGT          |

F, forward; R, reverse; HMGA2, high mobility group A2.

Chemical Reagent, Co. Ltd.) and 1 ml of 0.5% crystal violet (cat. no. C1701; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.) were added at room temperature, and the invaded cells were counted under a fluorescent microscope.

Flow cytometry. Both early and late stages of apoptosis rate of IU-TAB-1 cells was analyzed using flow cytometry according to the manufacturer's instructions. IU-TAB-1 cells (1x10⁶/ml) were cultured for 24 h at 37°C and harvested. Subsequently, 1 ml of pre-cooled PBS was added and the cells were centrifuged at 1,000 x g. Then, 10 µl of Annexin V-FITC (cat. no. 556547; BD Biosciences) and 10 µl of PI (cat. no. 556547; BD Biosciences) were added. The data were analyzed using CytExpert software v.2.0 (Beckman Coulter, Inc.).

Immunofluorescence. IU-TAB-1 cells (1x10⁶) were fixed in 4% paraformaldehyde for 30 min at room temperature. After washing twice with pre-cooled phosphate-buffered saline (PBS), the cells were permeabilized in 5% Triton X-100 (cat. no. CB1701; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.) for 20 min and blocked with 5% bovine serum albumin at 37°C for 1 h. The cells were then incubated with antibodies against β-catenin (1:200; cat. no. MAB37201; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.) overnight at 4°C, followed by incubation with Alexa Fluor 594-conjugated Goat Anti-Rabbit (1:200; cat. no. PAB160018; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.) for 30 min at room temperature and counterstained with 4',6-diamidino-2-phenylindole to identify the nuclei at 4°C for 5 min. Images were captured with a fluorescence microscope (DMIL LED; Leica Microsystems GmbH).

RT-qPCR. Total RNA was extracted from the cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific Inc.) according to the manufacturer's instructions. cDNA was synthesized using a reverse transcriptase kit (cat. no. 639505; Takara Bio Inc.). qPCR was performed with a CFX-Connect 96 real-time system (Bio-Rad Laboratories Inc.) using the SYBR Green PCR kit (cat. no. KM4101; KAPA Biosystems; Roche Diagnostics). qPCR was performed in duplicate and the thermocycling conditions were as follows: 95°C for 3 min for denaturation; 39 cycles of denaturation at 95°C for 5 sec, 56°C for 10 sec and 72°C for 25 sec; and 65°C for 5 sec and 95°C for 50 sec for annealing and extension. The results were analyzed by the 2^(-ΔΔCq) method (26). GAPDH was used as the reference gene. The primers were designed and configured by Wuhan Tianyi Huayu gene Biotechnology Co. Ltd. and are listed in Table I.

Western blotting. Following 48 h of treatment, the IU-TAB-1 (1x10⁶/ml) cells were washed with cold PBS and lysed using a lysis buffer (cat. no. 180006; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.), and the proteins were quantified by the bicinchoninic acid assay kit (cat. no. 180007; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.). The proteins (20 µg protein per lane) were separated on a 12% gel using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes. The membranes were blocked with a buffer containing 5% skimmed milk in PBS with 0.05% Tween-20 for 2 h at room temperature and incubated overnight at 4°C with primary antibodies against HMGA2 (1:1,000; cat. no. PAB40807; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.), Wnt3a (1:1,000; cat. no. PAB30170; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.), β-catenin (1:1,000; cat. no. MAB37201; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.), E-cadherin (1:1,000; cat. no. PAB33542; Bioswamp Wuhan Bienen Biotechnology Co. Ltd.), vimentin (1:1,000; cat. no. PAB40646; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.) and GAPDH (1:2,000; cat. no. PAB36264; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.). Following 3 washes with PBS/10% Tween-20, the membranes were incubated with horseradish peroxidase-conjugated secondary goat rabbit IgG (1:20,000; cat. no. PAB160011; Bioswamp Wuhan Bienen Biotechnology Co., Ltd.) for 2 h at room temperature. Protein bands were visualized by enhanced chemiluminescence color detection (Tanon-5200; Tanon Science and Technology Co., Ltd.) and analyzed using GIS software v.4.2 (Tanon Science and Technology Co., Ltd.).

Statistical analysis. All data are presented as the mean ± standard deviation. Statistical analysis was performed by one-way analysis of variance followed by the post-hoc Tukey's post-hoc test using SPSS 19.0 software (IBM Corp.). All figures were prepared using GraphPad Prism 5.0 software (Graph Pad Software Inc.). P<0.05 was considered to indicate statistical significance and all statistical analyses were based on 3 independent experiments.

Results

HMGA2 expression in IU-TAB-1, A549, HCT-116 and 293T cells. As shown in Fig. 1, compared with that in 293T cells, the protein expression of HMGA2 was significantly increased in IU-TAB-1, A549 and HCT-116 cells (P<0.05), with IU-TAB-1 cells demonstrating the highest expression. Hence, IU-TAB-1 cells were used for subsequent experimentation.

Controls for interference expression. mRNA expression of HMGA2 in the control, HMGA2-siRNA1, HMGA2-siRNA2, HMGA2-siRNA3 and negative control groups was observed to confirm HMGA2 inhibition by the interference vector (Fig. 2). The results confirmed that all 3 HMGA2 siRNAs significantly downregulated the expression of HMGA2 compared with the control and negative control IU-TAB-1 cells (P<0.05; Fig. 2).
HMGA2-siRNA3 induced the lowest HMGA2 expression among the 3 siRNAs and was hence used to silence HMGA2 in the subsequent experiments.

**si-HMGA2 attenuates EMT in IU-TAB-1 cells.** To observe the effect of HMGA2 on cell proliferation, migration and invasion, CCK-8 and Transwell assays were performed (Fig. 3A-C). Compared with the control, si-HMGA2 significantly suppressed cell proliferation, migration and invasion (P<0.05; Fig. 3A, B and D). Flow cytometry revealed that si-HMGA2 increased the apoptotic rate of IU-TAB-1 cells compared with control and negative control cells (Fig. 3D). The expression of EMT-related proteins (E-cadherin, vimentin, Wnt3a, Wnt5a, and β-catenin) was further assessed (Fig. 3E). The protein expression of vimentin, Wnt3a, Wnt5a and β-catenin were significantly decreased by si-HMGA2 (P<0.05; Fig. 3E), whereas that of E-cadherin was increased significantly compared with the control group (P<0.05; Fig. 3E), which indicated that HMGA2 silencing inhibited EMT in IU-TAB-1 cells.

**si-HMGA2 attenuates EMT in IU-TAB-1 cells via the Wnt/β-catenin pathway.** Immunofluorescence was conducted to observe the protein expression of β-catenin. Fig. 4A reveals that si-HMGA2 induced lower expression of β-catenin compared with that in the control and negative control groups. Proteins associated with the Wnt/β-catenin pathway were subsequently assessed using western blotting, which demonstrated that si-HMGA2 significantly downregulated the expression of Wnt3a, Wnt5a, vimentin and β-catenin compared with the control group (P<0.05; Fig. 4B), and upregulated the levels of E-cadherin, suggesting that si-HMGA2 inhibited the activation of Wnt/β-catenin signaling. To further study whether si-HMGA2 affects EMT in IU-TAB-1 cells by regulating the Wnt/β-catenin pathway, Wnt/β-catenin agonists or inhibitors were applied (Fig. 4B and C). Compared with the control and NC, the migration, invasion and expression of vimentin of cells treated with Wnt/β-catenin agonists were increased (P<0.05; Fig. 4B and C), whereas E-cadherin expression was significantly decreased (P<0.05; Fig. 4B and C). On the other hand, the combination of si-HMGA2 with Wnt/β-catenin inhibitors suppressed the migration, invasion, and expression of vimentin of IU-TAB-1 cells (P<0.05; Fig. 4B and C), whereas E-cadherin expression was increased significantly compared to the control and NC group (P<0.05; Fig. 4B and C).

**Discussion**

The human HMGA2 gene is located on the chromosome band 12q14-15 and contains at least 5 exons distributed in the ≥160-kb genomic region (6). HMGA2 is almost undetectable in healthy adult tissues; however, HMGA2 upregulation has been detected in breast cancer (27), sarcoma (28), pancreatic cancer (29) and non-small cell lung cancer (30) tissues. Whether HMGA2 is also upregulated in thymic cancer has not been studied to the best of our knowledge. IU-TAB-1, A549 and HCT-116 are common tumor cell lines (31-33). Studies have demonstrated that HMGA2 is highly expressed in a variety of malignant tumors, including lung, colon and ovarian cancer (8-12), and its enhanced expression is closely related to enhanced tumor aggressiveness and disease prognosis (8-12). Hence, we speculated that the occurrence and development of thymic cancer is also related to the abnormally high expression of HMGA2. Hence, in the present study, A549, HCT-116 and 293T cells were used as controls. The results of the present study demonstrated that HGMA2 expression in IU-TAB-1 cells was significantly higher compared with that in A549 and HCT-116 cells, which suggested that HMGA2 expression was significantly increased in thymic cancer cells.

E-cadherin loss is a prominent feature of cellular EMT (34). Decreased E-cadherin levels can lead to reduced cell adhesion and allow cells to acquire characteristics that enable invasion.
and metastasis (35). Studies have reported mutations in the E-cadherin gene or downregulation of E-cadherin expression in lung, breast, gastric and other epithelial cancer types (36,37). Vimentin is one of the main components of the medium fibers of fibroblasts (38). When E-cadherin is lost, the expression of vimentin and N-cadherin increases and cells acquire an interstitial phenotype (39). The present study demonstrated that HMGA2 silencing upregulated the expression of E-cadherin and downregulated that of vimentin, which suggested that inhibition of HMGA2 suppressed EMT in thymic cancer cells. Cell infiltration is an important feature of malignant tumors, wherein EMT serves an important role (13). Cells undergoing EMT can grow on and penetrate Matrigel, revealing that EMT may be an important factor for tumor cells to break through the basement membrane (40). In clinical treatment, tumor cells metastasize to other sites through blood vessels and lymphatic vessels, representing further tumor deterioration and a poor clinical prognosis. E-cadherin expression is inversely related to the degree of tumor differentiation and lymph node metastasis (39). After injection of E-cadherin-deficient tumor cells into nude mice, carcinogenicity and metastasis were significantly enhanced (41). In the present study, HMGA2 silencing inhibited the proliferation, migration and invasion of thymic cancer cells, while promoting cell apoptosis. In the present study, further evaluation of the expression of EMT-associated proteins demonstrated that when HMGA2 was suppressed, E-cadherin was upregulated and vimentin was downregulated, which suggested that inhibition of HMGA2 suppressed EMT in thymic cancer cells.

β-catenin is the core molecule of the Wnt pathway and its accumulation in the cytoplasm is the key to Wnt/β-catenin activation (42). When Wnt signaling is activated, the
Figure 4. si-HMGA2 attenuates EMT in IU-TAB-1 cells via the Wnt/β-catenin pathway. (A) β-catenin expression was observed by immunofluorescence (scale bar, 100 µm). (B) Protein expression of Wnt3a, Wnt5a, β-catenin, E-cadherin and vimentin was measured by western blotting. (C) Effect of si-HMGA2 in combination with Wnt/β-catenin pathway agonists (SKL2001) or inhibitors (XAV-939) on IU-TAB-1 cell migration and invasion (n=3). *P<0.05 vs. control. HMGA2, high mobility group A2; si, small interfering; EMT, epithelial-mesenchymal transition; NC, negative control; Control, IU-TAB-1 cells.
Wnt protein binds to the extracellular domain of frizzled protein. β-catenin cannot be degraded, and a large amount of free β-catenin accumulates in the cytoplasm, enters the nucleus and combines with the transcription factor T cytokine/lymphocyte enhancing factor to regulate cell proliferation and apoptosis (43). Qin et al (44) demonstrated that the expression of β-catenin in SNK-6 and YTS cell lines was significantly higher compared with that in normal natural killer cells and was significantly higher in natural-killer/T cell lymphoma tissues compared with reactive hyperplasia of lymph nodes. Ebert et al (45) demonstrated that β-catenin expression was increased in gastric cancer tissues, and a β-catenin gene mutation was detected compared to the normal gastric tissue. Shi and Yin (46) studied the expression of β-catenin and hepatocyte nuclear factor-1α in hepatocellular carcinoma tissues and their effects on the prognosis of hepatocellular carcinoma. The results of the aforementioned study revealed that the clinical prognosis of patients with abnormal β-catenin expression was significantly worse compared with that of patients with normal β-catenin expression, which suggested that abnormal expression of β-catenin was related to the development of hepatocellular carcinoma (46). The findings of the present study revealed that when the expression of HMGA2 was silenced, β-catenin was downregulated, suggesting that HMGA2 inhibition reduced β-catenin accumulation of thymic cancer cells. The present study further examined the effect of si-HMGA2 on the Wnt/β-catenin signaling pathway and demonstrated that HMGA2 silencing inhibited Wnt/β-catenin signaling. This finding indicated that the effect of HMGA2 on EMT in thymic cancer cells may be achieved by regulating the activity of Wnt/β-catenin signaling. Inhibiting HMGA2 activity inhibited the EMT activity of HMGA2 thymogenic cancer cells in the present study. In the present study, cells were treated with si-HMGA2 in combination with Wnt/β-catenin agonists (SKL2001) or inhibitors (XAV-939), and the changes in EMT in thymic cancer cells were observed. In the present study, cell migration and invasion and vimentin expression were significantly enhanced by Wnt/β-catenin agonists compared with that in control cells, while the expression of E-cadherin was significantly decreased. Correspondingly, Wnt/β-catenin inhibitors demonstrated the opposite effect. These findings demonstrated that HMGA2 inhibition suppressed Wnt/β-catenin activation and inhibited EMT in thymic cancer cells, providing a potential therapeutic strategy for the clinical treatment of thymic cancer.

The present study had several limitations. Firstly, E-cadherin is the only bona fide Wnt target investigated in the present study, hence the association between HMGA2 and Wnt signaling requires further investigation. T cell factor/lymphoid enhancer factor activity should be detected in future studies. Secondly, the use of just one thymic cell line is a limitation of the present study. More cell lines and clinical samples should be investigated in future studies to verify the findings of the present study.

In conclusion, HMGA2 may be a key protein that regulates EMT in thymic cancer cells. In the present study, inhibition of HMGA2 significantly attenuated cell proliferation, migration and invasion, and promoted apoptosis, and this mechanism may be related to Wnt/β-catenin signaling.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The data used in this study are available from the corresponding author upon request.

Authors’ contributions
ST and JC performed the experiments, collected and analyzed the data. ST drafted the manuscript. JC revised the manuscript for important intellectual content. ST and JC confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Noriyuki T: Thymic epithelial tumors. Haigan 47: 181-185, 2007.
2. Ji W, Feng QF, Zhou ZM, Wang M, Chen DF, Zhang HX, Xiao ZF, Wang LH and Yin WB: Treatment and prognosis analysis of 73 cases of thymic carcinoma. Chin J Radiat Oncol 15: 97-100, 2006.
3. Kondo K and Monden Y: Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan. Ann Thorac Surg 76: 878-884, discussion 884-885, 2003.
4. Lamarcia A, Moreno V and Feliu J: Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev 39: 413-420, 2013.
5. Ozturk N, Singh I, Mehta A, Braun T and Barreto G: HMGA proteins as modulators of chromatin structure during transcriptional activation. Front Cell Dev Biol 2: 5, 2014.
6. Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, Hearn SA, Myers MP and Lowe SW: A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503-514, 2006.
7. Cleynen I and Van de Ven WJ: The HMGA proteins: A myriad of functions (Review). Int J Oncol 32: 289-305, 2008.
8. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, Kowalski J, Bhattacharya R, Ashfaq R and Resar LM: HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 6: 743-750, 2008.
9. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348-356, 2008.
10. Huang ML, Chen CC and Chang LC: Gene expressions of HMGL-C and HMGL-Y are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis 24: 1281-1286, 2009.
11. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A and Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 22: 43-49, 2009.
12. Bartuma H, Panagopoulos I, Collin A, Trombeta D, Domanski HA, Mandahl N and Mertens F: Expression levels of HMGA2 in adenocarcinomas and breast cancer metastases. Mol Cancer 8: 36, 2009.

13. Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33, 2009.

14. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.

15. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.

16. Cheng P, Zheng CN, Ben W, Gao HJ, Niu WB, He ZB, Gao C, Zou ZJ, Ma C, Chen J, et al.: Norcantharidin inhibits colon cancer cell EMT process through blocking cvl6/ERK-ETS1 signal pathway. Chin J Curr Adv Gen Surg 10: 757-762, 2014 (In Chinese).

17. Lin Q, Zhou CR, Bai MJ, Zhu D, Chen JW, Wang HF, Li MA, Wu C, Li ZR and Huang MS: Exosome-mediated miRNA delivery promotes liver cancer EMT and metastasis. Am J Transl Res 12: 1080-1095, 2020.

18. Zha L, Zhang J, Tang WX, Zhang N, He M, Gao Y and Wang ZW: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci 58: 724-733, 2013.

19. Eugenio Z, Gabri VDP, Gray PC and Marriana KJ: Epithelial plasticity in cancer: unmasking a microRNA network for TGF-β, Notch-, and Wnt-mediated EMT. J Oncol 2015: 198967, 2015, 2015.

20. Li Y, Ma L, Zhang YL, Jiang T, Bi GB and Sao C: Expression and clinical significance of β-catenin and axin in ovarian epithelial cell carcinoma. J Modern Integ Med 26: 2871-2873+2957, 2017.

21. Huang XW, Cui WW, Wang BF, Song YL, Liang YJ and Dong Y: Abnormal activation of wnt/β-catenin signaling pathway in nasopharyngeal carcinoma. J Tongji Med Univ 46: 295-298, 2017.

22. Zha L, Zhang J, Tang W, Zhang N, He M, Guo Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig Dis Sci 58: 724-733, 2013.

23. Pan CB, Zhao XP and Zhang H: High expression of HMGA2 promotes metastasis of tongue carcinoma through EMT. The 13th National Conference on Oral and Maxillofacial Surgery.

24. Li W, Wang J, Zhang D, Zhang X, Xu J and Zhao L: MicroRNA-98 targets HMGA2 to inhibit the development of retinoblastoma through mediating Wnt/β-catenin pathway. Cancer Biomark 25: 79-88, 2019.

25. Tan S, Zhang QG, Zhang L, Liu N and Cheng Y: Expression and clinical significance of β-catenin and c-myc in invasive thymoma. J Chin Med Univ 34: 464-465, 2005.

26. Livak KJ and Schmittgen TDL: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔ Ct Method. Methods 25: 402-408, 2001.

27. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U and Bullerdiek J: Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: Relationship to histologic grade. Mol Carcinog 19: 153-156, 1997.

28. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O and Myklebost O: HMGC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 14: 2935-2941, 1997.

29. Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiapetita G, Fusco A and Atomi Y: An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer 89: 2104-2109, 2003.

30. Meyer B, Loeckche S, Schultz A, Weigel T, Sandkamp M, Goldmann T, Vollmer E and Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog 46: 503-511, 2007.

31. Arsianti A, Fadilah F, Bahtiar A and Tanimoto H: Pychochemical analysis and in vitro cytotoxicity of seaweed sargassum sp. Against colon HCT-116 and Lung-A549 cancer cells. In: Proceedings of The 18th World Congress of Basic and Clinical Pharmacology (WCP2018). WCP2018, Kyoto, 2018.

32. Gökkmen-Polar Y, Sanders KL, Goswami CP, Cano OD, Zaheer NA, Jain KK, Kesler KA, Nelson RP Jr, Vance GH, Smith D, et al.: Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Lab Invest 92: 1564-1573, 2012.

33. Lee HS, Jang HJ, Lo EM, Truong CY, Groth SS, Friedman JS, Sugabaker DJ and Burt BM: Podoivine‑iodine results in rapid killing of thymic epithelial tumour cells through cellular fixatio. Interact Cardiovasc Thorac Surg 28: 353-359, 2019.

34. Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, Wouters BG, Lamming G and Voojs M: E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol 99: 392-397, 2011.

35. Fransvea E, Angelotti U, Antonaci S and Giannelli G: Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557-1566, 2008.

36. Busssemakers MJK, van Mooijen RGG, Girola LA, Ichikawa T, Isaacs JT, Takechi M, Debruyne FM and Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52: 2916-2922, 1992.

37. Fearon ER: Cancer: Context is key for E-cadherin in invasion and metastasis. Curr Biol 29: R1140-R1142, 2019.

38. Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68: 3033-3046, 2011.

39. Sun S, Sun W, Xia L, Liu L, Du R, He L, Li R, Wang H and Huang C: The T-box transcription factor Brachyury promotes renal interstitial fibrosis by repressing E-cadherin expression. Cell Commun Signal 12: 76, 2014.

40. Liu Z, Jin H, Yang S, Zhang ZY, Wen B and Zhou SB: SDC1 knockdown induces epithelial-mesenchymal transition and invasion of gallbladder cancer cells via the ERK/Snail pathway. J Inter Med Res 8: 30006520947883, 2020.

41. Telford BJ, Chen A, Beetham H, Frick J, Brew TP, Gould CM, Single A, Godwin T, Simpson KJ and Guilford P: Synthetic lethal screens identify vulnerabilities in GPCR signaling and cytoskeletal organization in E-Cadherin-Deficient cell. Mol Cancer Ther 14: 1213-1223, 2015.

42. Clevers H: Wnt/β-catenin signaling in development and disease. Cell 127: 469-480, 2006.

43. Jiang D, Nai MY, Chen JZ and Wei LX: Effect of silencing HMGA2 on signal transduction pathway of Wnt/β-catenin in gastric cancer cells. World Chin J Dig 21: 1062-1069, 2013 (In Chinese).

44. Qin BB, Li YQ, Li XL, Lu LS, Zhang XD and Zhang MZ: Expression of Wnt/β-catenin pathway key molecules in NK/T cell lymphoma and its clinical significance. J Jilin Univ 41: 1564-1573, 2012.

45. Ebert MP, Fei G, Kahmann S, Müller O, Yu J, Sung JJ and Malfertheiner P: Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis 23: 87-91, 2002.

46. Shi JF and Yin F: Expression of β-catenin and hepatocyte nuclear factor-1α in HCC and its effect on prognosis. Chin J Oncol 36: 587-591, 2014.